

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA HEALTH GROUP INC.



(中國醫療集團有限公司)

(Carrying on business in Hong Kong as “萬全醫療集團”)

(Formerly known as “Venturepharm Laboratories Limited”)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

INSIDE INFORMATION POSSIBLE DELAY IN PUBLICATION OF THE 2022 ANNUAL RESULTS AND DESPATCH OF THE 2022 ANNUAL REPORT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of China Health Group INC. (the “**Company**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong).

POSSIBLE DELAY IN PUBLICATION OF ANNUAL RESULTS

The Board wishes to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that the preparation for the audit of the financial statements of the Group for the year ended 31 December 2022 has been delayed due to the valuation of accounts receivable, the auditor needs to have further communication with the appraiser, as well as the confirmation outstanding. As such, the auditor requires more time for conducting the audit of the 2022 annual results and it is expected that the Company may not be able to publish the audited annual results for the year ended 31 December 2022 (the “**2022 Annual Results**”) on or before 14 April 2023.

The Company will use its best endeavours to publish the 2022 Annual Results and despatch the annual report for the year ended 31 December 2022 (the “**2022 Annual Report**”) to the Shareholders as soon as possible. It is expected that the 2022 Annual Results will be published and 2022 Annual Report will be despatched on or before 14 April 2023.

Pursuant to Rules 18.49 and 18.48A of the GEM Listing Rules, the Company is required to publish the 2022 Annual Results not later than three months after the end of the financial year of the Company, i.e. on or before 31 March 2023 and despatch its 2022 Annual Report to the Shareholders on or before 31 March 2023. Under Rule 18.49 of the GEM Listing Rules, the preliminary announcement in relation to the 2022 Annual Results shall be based on the Company's financial statements for the year ended 31 December 2022 which shall have been agreed with the auditor.

The possible delay in publication of the 2022 Annual Results and the despatch of the 2022 Annual Report if materialised, will constitute non-compliance of Rules 18.49 and 18.48A of the GEM Listing Rules. The Company wishes to emphasise that the operations of the Group remain normal. The Company will publish further announcement(s) in due course to inform the Shareholders of

(i) the date of the meeting of the Board to consider and approve the 2022 Annual Results; (ii) the date of the release of the 2022 Annual Results and the despatch of the 2022 Annual Report; and
(iii) any material development. Save as disclosed above, the Company does not have any other unpublished inside information.

POSSIBLE SUSPENSION OF TRADING

Pursuant to Rule 17.49A of the GEM Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer's securities if an issuer fails to publish periodic financial information in accordance with the GEM Listing Rules, and the suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information. Accordingly, if the possible delay in publication of the 2022 Annual Results and the despatch of the 2022 Annual Report materialized, trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on 3 April 2023 until the publication of the announcement in relation to the 2022 Annual Results and the despatch of the 2022 Annual Report by the Company.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
China Health Group Inc.
William Xia GUO
Chairman

Hong Kong, 28 March, 2023

As at the date of this supplemental announcement, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non-executive Director, being Ms. ZHANG Li; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling.

This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7days from the date of its posting and on the Company’s website at www.chgi.net.